Sung Ji Nam
Stock Analyst at Scotiabank
(3.50)
# 924
Out of 4,711 analysts
60
Total ratings
53.7%
Success rate
4.09%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Maintains: Sector Outperform | $50 → $54 | $47.94 | +12.64% | 4 | Nov 19, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $7 → $6 | $1.97 | +204.57% | 4 | Nov 11, 2024 | |
| VCYT Veracyte | Maintains: Sector Outperform | $40 → $44 | $40.89 | +7.61% | 4 | Nov 8, 2024 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $37 → $44 | $27.53 | +59.83% | 5 | Nov 6, 2024 | |
| CDNA CareDx | Maintains: Buy | $40 → $35 | $20.61 | +69.82% | 4 | Nov 5, 2024 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $83 → $88 | $73.17 | +20.27% | 1 | Oct 31, 2024 | |
| BDSX Biodesix | Initiates: Sector Outperform | $3 | $1.57 | +91.08% | 1 | Sep 16, 2024 | |
| BNGO Bionano Genomics | Downgrades: Sector Perform | $6 → $1 | $0.20 | +412.82% | 5 | Aug 28, 2024 | |
| ILMN Illumina | Maintains: Sector Outperform | $176 → $164 | $136.02 | +20.57% | 9 | Aug 15, 2024 | |
| MYGN Myriad Genetics | Maintains: Sector Outperform | $29 → $34 | $13.36 | +154.49% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $59.40 | +17.85% | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $7.73 | -22.38% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $36 | $31.67 | +13.67% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $6.39 | +134.74% | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $718 | $524.05 | +37.01% | 11 | Feb 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $18.34 | - | 3 | Nov 24, 2020 |
Twist Bioscience
Nov 19, 2024
Maintains: Sector Outperform
Price Target: $50 → $54
Current: $47.94
Upside: +12.64%
Pacific Biosciences of California
Nov 11, 2024
Maintains: Sector Outperform
Price Target: $7 → $6
Current: $1.97
Upside: +204.57%
Veracyte
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $40.89
Upside: +7.61%
Castle Biosciences
Nov 6, 2024
Maintains: Sector Outperform
Price Target: $37 → $44
Current: $27.53
Upside: +59.83%
CareDx
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $20.61
Upside: +69.82%
Bio-Techne
Oct 31, 2024
Maintains: Sector Outperform
Price Target: $83 → $88
Current: $73.17
Upside: +20.27%
Biodesix
Sep 16, 2024
Initiates: Sector Outperform
Price Target: $3
Current: $1.57
Upside: +91.08%
Bionano Genomics
Aug 28, 2024
Downgrades: Sector Perform
Price Target: $6 → $1
Current: $0.20
Upside: +412.82%
Illumina
Aug 15, 2024
Maintains: Sector Outperform
Price Target: $176 → $164
Current: $136.02
Upside: +20.57%
Myriad Genetics
Aug 13, 2024
Maintains: Sector Outperform
Price Target: $29 → $34
Current: $13.36
Upside: +154.49%
Jun 27, 2024
Initiates: Sector Outperform
Price Target: $70
Current: $59.40
Upside: +17.85%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $7.73
Upside: -22.38%
Jan 5, 2023
Initiates: Sector Outperform
Price Target: $36
Current: $31.67
Upside: +13.67%
Jan 5, 2023
Initiates: Sector Outperform
Price Target: $15
Current: $6.39
Upside: +134.74%
Feb 2, 2022
Maintains: Buy
Price Target: $718
Current: $524.05
Upside: +37.01%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $18.34
Upside: -